Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target The firm cites the company’s catalyst path in 2026 for the upgrade. Wells sees upside from MRT-8102’s Phase 1 update in the first half of 2026 and likely disclosure of Novartis’ (NVS) plans for MRT-6160. The MRT-8102 Phase 1 update should be “de-risking,” the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- Monte Rosa Therapeutics presents preclinical data on MRT-8102
- Monte Rosa Therapeutics Reports Strong Revenue Growth
- Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating
- Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating